Don't forget Grecian Formula and Grecian Urns. Two exceptional products with Grecian in the name.
Not there yet, but keep watching this page: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/distribution-map.html#areas
Smith, I had a similar story with the same connection to ACAD. My father died last December from complications from Parkinson's Disease. He had dementia and it was horrible. I hoped that the drug would be available before he died, but this did not happen. Ultimately, my father died from aspiration pneumonia resulting from a broken hip. In hindsight, I am thankful for the relief that came from his death. Very, very hard. I am certain that there are many people in the position that you are in and I was in. I send the best to you.
The current shares that I'm holding were purchased at $0.97, $1.73, $1.50, and $1.59 - mostly 2012, but some in 2010. Feeling lucky. I sold some prematurely.
It is going to be very interesting to see what happens over the next couple of days. Someone on this board speculated that the shares were already sold. If so, I don't suspect the the price will drop to $4.00. Like RConre, I hope NVAX puts out a press release explaining their need to raise more money. They better have a good reason that pays off for shareholders quickly.
Trip, Do you still live in CH? Maybe one of these days we'll get to have that drink at the NST or The C.
"Although the science of making a vaccine against MERS is feasible—unlike, say, HIV, which has stymied researchers for decades—neither the market economy nor the vaccine development process is likely to support it, experts say."
"Several academic researchers agreed that it doesn't make sense to spend time and money developing a MERS vaccine right now. Despite its recent spread, the disease, first identified in 2012, has been relatively contained so far and doesn't seem to be as contagious as SARS. Also, like any medication, a vaccine would certainly have side effects."
"Developing a vaccine for camels would be cheaper, faster, and easier than developing one for people, he said, without the same level of safety concerns. He thinks it's possible to get a vaccine into camels even before October's hajj pilgrimage."
In this case I might agree with novasomes because if anyone can identify "unreal insanes theories" it is him.
This does not enhance your vast stock market knowledge. Not Very Credible.
Anti-hero, You really know nothing about the company and its prospects do you?
And the fact that other biotechs are doing exactly the same thing doesn't mean a thing right? Market rules. Individual stocks don't seem to matter. Someone mentioned yesterday the impacts of ETFs. I wonder if ETFs are causing (or at least impacting) this drop.
I actually performed an analysis of daily share price closes between NVAX and IBB for ytd 2014. Using the Excell CORREL function I found of 0.604. I would call this a high correlation. Not having done this for many biotech stocks, I don't know what is typical. Correlation ranges between 0 and 1.
Sure looks like we are reaching the bottom of the slide. Maybe I buy tomorrow?